| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| Carolyn Cross |
156,314,029 |
£18,992,154 |
| Nicolas Loebel |
3,538,991 |
£429,987 |
| Junaid Bajwa |
1,193,697 |
£145,034 |
| Jean Duvall |
1,163,529 |
£141,369 |
| Jean Charest |
353,356 |
£42,933 |
| Carolyn Cross |
119,258,222 |
£14,489,874 |
| M&G Plc |
67,254,901 |
£8,171,470 |
| hInsight-NX, LLC |
42,272,654 |
£5,136,128 |
| Robert Cross |
37,772,652 |
£4,589,377 |
| Albemarle Life Sciences Fund |
15,105,882 |
£1,835,365 |
| CRUX Asset Management |
9,298,090 |
£1,129,718 |
| Chelverton Asset Management |
7,957,311 |
£966,813 |
| 08:14 |
20,000 @ 12.05p |
| 08:07 |
40,000 @ 12.50p |
| Chair |
Jean Charest |
| CEO |
Carolyn Cross |
Top of Page
You are here:
research